Actively Recruiting
Evaluating a New Six-Month Treatment Regimen for Multidrug-Resistant Tuberculosis Patients in France Using BPaLM Compared to Conventional Therapy
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-09-16
55
Participants Needed
5
Research Sites
78 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of a new six-month treatment regimen called BPaLM for adults with multidrug-resistant tuberculosis MDR-TB in France. This Phase 3 trial compares BPaLM to a long, conventional treatment regimen using an external historical control group. The study adapts treatment based on rapid molecular testing for fluoroquinolone resistance to tailor therapy for each patient. Participants will undergo rapid molecular testing at screening to determine fluoroquinolone resistance. Those susceptible receive BPaLM resistant cases get a regimen called BPaLC with clofazimine replacing moxifloxacin inconclusive results lead to BPaLMC, which is adjusted later based on further testing. Bedaquiline doses vary by group one receives 400 mg daily for 2 weeks then 200 mg thrice weekly for 22 weeks, another receives 200 mg daily for 8 weeks then 100 mg daily for 16 weeks. During the study, participants are closely monitored from treatment start through 18 months. Assessments include sputum culture conversion, treatment adherence, drug resistance, quality of life, and safety. Researchers also evaluate pharmacokinetics and health economics. The study involves regular visits, tests, and questionnaires to measure treatment effectiveness and participant satisfaction over time.
CONDITIONS
Brief Title
Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)
Research Team
L
Lorenzo GUGLIELMETTI, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here